Novel metrics for evaluating decision making in a 'Treat and Extend' regimen for neovascular age related macular degeneration.

These metrics for evaluating the decision making aspect of disease activity monitoring may be useful for monitoring performance and have given us a more realistic view and expectations of what can be achieved using this regime to optimise the timing of injections.